Abstract 1855P
Background
Over the last few decades, there has been a significant improvement in the survival rates of cancer patients, due to early diagnosis and advancements in treatment options. But survival benefits can only be maximized if people are able and willing to take their oncology treatment. The Cancer Therapy Satisfaction Questionnaire (CTSQ) offers a standardized way to collect information about treatment satisfaction directly from oncology patients. The objective of this study was to explore the use of the CTSQ in clinical trials and non-clinical studies.
Methods
A scoping review of scientific papers was conducted for CTSQ use using multiple electronic databases including MEDLINE, EMBASE, and Cochrane using the OVID interface. In addition, the ClinicalTrials.gov platform was also searched to identify clinical trials and non-clinical studies where CTSQ was included.
Results
Forty- two atricles and 23 clinical trials/studies were identified. The CTSQ was used in 14 different types of cancer, including solid and hematological tumors. 29.1% of research explored oral treatments, 27.3% IV treatment, and 1.8% both. In the 55 comparative studies with results the CTSQ showed a difference between treatments in 54.2% of the scientific papers. The CSTQ has been predominantly used in interventional studies to evaluate secondary outcomes of Phase III and IV clinical trials. The CTSQ has been used in more than 50 countries/languages.
Conclusions
The CTSQ is a disease-specific questionnaire to evaluate treatment satisfaction, and is being used across multiple settings, countries and studies. However, it is still only included in a small fraction of clinical trials/studies globally. As patient-focused drug development and personalized medicine/care evolves, considering not just the molecular traits of patients but also their perspectives on treatment, is likely to become more important. Although the US FDA and EMA have already expressed an interest in patient-reported efficacy and tolerability in clinical trials, treatment satisfaction may be an important addendum to understand how treatment effects in clinical trials may translate to treatment-related behaviors in routine clinical care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA.
Funding
IQVIA.
Disclosure
C. Navas: Financial Interests, Personal, Other, Employee: IQVIA.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12